Some aspects of host response to levamisole after chemotherapy in a murine leukemia.
Levamisole (LMS), when used with an effective remission-inducing drug in leukemic mice, resulted in a high percentage of long-term survivors. Histologic examination of spleens from treated leukemic mice showed that LMS caused an earlier return of lymphoid cells in the splenic lymphoid follicles and lymphoid elements in the red pulp.
D000818:Animals; D002330:Carmustine / Q000627:therapeutic use*; D007111:Immunity, Cellular; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000276:immunology; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009929:Organ Size; D012075:Remission, Spontaneous; D013154:Spleen / Q000276:immunology
D007978:Levamisole; D002330:Carmustine